Subscribe now! Get as
Pfizer Inc said Tuesday that the U. S. Food and Drug Administration is not yet in the process of the U. S. Food and Drug Administration. The U. S. Department of Health has extended the Emergency Use Authorization (EUA) for the company’s bivalent COVID-19 vaccine and his spouse BioNTech SE as a single booster dose for certain children.
The amended authorization applies to children aged six months to 4 years who have completed their initial three-dose vaccination with the original Pfizer vaccine.
In December, the U. S. fitness regulator was held in the U. S. The U. S. government legalized the updated Pfizer/BioNTech vaccine as a third dose for other people six months to four years of age who have not finished their number one vaccine series or who have not yet won the third dose.
Read also: Is the H3N2 virus life-threatening?Could it be Covid? Experts respond
The fitness regulator’s amended authorization is based on the knowledge of 60 children, of the broadest age group, who finished vaccination number one with 3 doses and gained a booster shot from Pfizer/BioNTech, and showed an immune reaction to SARS-CoV-2 of viral origin and Omicron BA. 4/BA. 5.
Vaccines for Younger Children in the U. S. UU. no were approved until June of last year, making them the newest organization to be eligible for vaccination.
Read also: Foreign tourists from China after 3 years, signals the total end of ‘zero-Covid’
Government knowledge shows that only 2. 7% of eligible children under the age of two and less than five percent of eligible children aged two to four have completed their number one immunization series as of November 30, representing slow absorption of initial doses of the vaccine in young children.